FMP
NASDAQ
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
2.92 USD
0.0976 (3.34%)
Valuation Date:
Apr 29, 2024 10:20 AM
Share Price on Valuation Date
$2.92
Stock Beta
0.35
Shares Outstanding
8107120